Prioritizing research challenges and funding for allergy and asthma and the need for translational research-The European Strategic Forum on Allergic Diseases

Agache I., Annesi-Maesano I., Bonertz A., Branca F., Cant A., Fras Z., ...More

ALLERGY, vol.74, no.11, pp.2064-2076, 2019 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 74 Issue: 11
  • Publication Date: 2019
  • Doi Number: 10.1111/all.13856
  • Title of Journal : ALLERGY
  • Page Numbers: pp.2064-2076
  • Keywords: allergic diseases, asthma, big data, environmental health, exposome, implementation science, quality criteria, translational research, PRECISION MEDICINE, IMPLEMENTATION SCIENCE, DRUG DEVELOPMENT, FOOD ALLERGY, OPPORTUNITIES, ASSOCIATION, BIOMARKERS, GUIDELINES, EXPOSOME, BIRTH


The European Academy of Allergy and Clinical Immunology (EAACI) organized the first European Strategic Forum on Allergic Diseases and Asthma. The main aim was to bring together all relevant stakeholders and decision-makers in the field of allergy, asthma and clinical Immunology around an open debate on contemporary challenges and potential solutions for the next decade. The Strategic Forum was an upscaling of the EAACI White Paper aiming to integrate the Academy's output with the perspective offered by EAACI's partners. This collaboration is fundamental for adapting and integrating allergy and asthma care into the context of real-world problems. The Strategic Forum on Allergic Diseases brought together all partners who have the drive and the influence to make positive change: national and international societies, patients' organizations, regulatory bodies and industry representatives. An open debate with a special focus on drug development and biomedical engineering, big data and information technology and allergic diseases and asthma in the context of environmental health concluded that connecting science with the transformation of care and a joint agreement between all partners on priorities and needs are essential to ensure a better management of allergic diseases and asthma in the advent of precision medicine together with global access to innovative and affordable diagnostics and therapeutics.